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ABSTRACT
Background: BRAFV600E mutation is present in a subset of pediatric brain tumors.
Vemurafenib is an oral, selective ATP-competitive inhibitor of BRAFV600E kinase. The
goal of this multi-center study conducted through the Pacific Pediatric Neuro-Oncology
Consortium (PNOC) was to determine the recommended phase 2 dose (RP2D) and
dose limiting toxicities (DLTs) in children < 18 years with recurrent or progressive
BRAFV600E mutant brain tumors.
Results: Nineteen eligible patients were enrolled. Eleven patients had received
three or more prior therapies. Data reported are from the start of treatment for
the first patient (April 30 2014) through August 31 2019. The RP2D was defined
as 550 mg/m2 twice daily after DLT criteria adjustment for rash. Related grade ≥ 3
adverse events included secondary keratoacanthoma (n = 1); rash (n =16); and fever
(n = 5). Subjects received a median of 23 cycles (range 3–63). Four patients remain
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on treatment. Centrally reviewed best radiographic responses included 1 complete
response, 5 partial responses, and 13 stable disease. The steady-state area under the
curve (AUC0-∞median) was 604 mg*h/L (range 329–1052).
Methods: Vemurafenib was given starting at 550 mg/m2, twice daily which
corresponds to the adult RP2D. Adverse events were graded using the NIH Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0. Central imaging review
was performed. Pharmacokinetic sampling was performed.
Conclusions: Vemurafenib has promising anti-tumor activity in recurrent BRAF
V600E-positive brain tumors with manageable toxicity. A phase 2 study is ongoing
(NCT01748149).

Herein we report on a multi-center phase 1 study
conducted through the Pacific Pediatric Neuro-Oncology
Consortium (PNOC) of vemurafenib in children < 18
years of age with recurrent or progressive BRAFV600E
mutant brain tumors. At the time of trial development,
there were no published reports of vemurafenib safety,
efficacy, CNS penetration or pharmacokinetics in children
with gliomas.

INTRODUCTION
BRAFV600E is one of the most common oncogenic
mutations in human tumors, found in 50% of metastatic
melanomas, 10% of metastatic colon carcinomas, and
30% of papillary thyroid carcinomas [1]. This point
mutation results in a constitutively active form of BRAF
that functions as a monomer and is resistant to feedback
inhibition [2]. Small molecule inhibitors that specifically
target the BRAFV600E kinase domain have been developed
and have shown significant, albeit transient, activity in
adult metastatic melanomas with BRAFV600E mutations
[3]. An unexpected side effect of this class of inhibitors
is a high risk of secondary squamous cell carcinoma
(keratoacanthoma). These occur in approximately 25%
of treated adults and have been demonstrated to contain
activating RAS mutations (or less frequently NOTCH
or TGF deletions) and show growth stimulation through
paradoxical activation of wild type RAF dimers by BRAF
inhibitors [4].
Gliomas are the most common subgroup of pediatric
brain tumors [5]. Children with low grade gliomas (WHO
grade 1 and 2) have an excellent prognosis when these
lesions can be totally resected, but often require adjuvant
therapy when gross total resection cannot be achieved.
Children with high grade gliomas (WHO grade 3 and 4)
have a poor prognosis, despite aggressive multimodal
therapy and no standard therapy, other than surgical
resection and radiotherapy, has been established [6].
Until recently, adjuvant treatment for children
with gliomas was limited to cytotoxic chemotherapy and
radiation due to the lack of knowledge of the biological
drivers of these tumors and a lack of available agents
that could target such drivers [7]. Over the past ten
years, many groups have demonstrated a high frequency
of alterations in the RAS/RAF/MAPK pathway in
pediatric gliomas. BRAFV600E mutations, in particular,
are found in 5% of malignant astrocytomas, 9% of
pilocytic astrocytomas, 50% of gangliogliomas and
66% of pleomorphic xanthoastrocytomas [8]. Our group
demonstrated significant anti-tumor efficacy of PLX4720
(tool compound analog of the BRAFV600E-specific inhibitor
vemurafenib) in intracranial xenografts harboring
BRAFV600E-mutant gliomas, while showing no efficacy
against BRAF-wild type xenografts [9].
www.oncotarget.com

RESULTS
Subject characteristics
Among 19 eligible patients, one was not compliant
with medications during the DLT period and therefore not
fully evaluable for estimation of RP2D or PK analysis.
Table 1 summarizes the subject characteristics. The most
common histology was pilocytic astrocytoma (n=10).
Although this trial was open to both low and high-grade
tumors, only patients with low-grade tumors enrolled in
the safety study. While this trial was open at multiple sites,
the relative scarcity of pediatric patients with recurrent
BRAFV600E mutant brain tumors led to expected relatively
slow accrual.

Toxicities
The most common toxicity was maculopapular rash
(Table 2). This is a known side effect of vemurafenib and
responded well to holding the drug and supportive care.
Two of the three patients initially treated at both Dose
Level 0 and −1 had grade 3 rash and met DLT criteria.
As these rashes resolved shortly after holding drug
with appropriate supportive care and did not recur with
restarting drug, we subsequently amended the study to
exclude rash that resolved within 7 days with supportive
care as a DLT. As a consequence, rather than further dose
reductions, additional patients were treated at dose level
−1. Dose level −1 was subsequently declared safe without
further rash and patients were then escalated back up
to dose level 0, which was also well tolerated and was
determined as the RP2D.
One thirteen-year-old patient developed several
facial lesions during Cycle 4 that were tissue confirmed
squamous cell carcinoma (SCC).
1943
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Table 1: Patient characteristics
Age in years, at study enrollment, median (min, max)
Number of courses of vemurafenib: median (min, max)
Number of Prior Therapies
One
Two
Three or more
Gender
Males
Females
Race
White, non-Hispanic
Black
Unknown
Diagnosis
Astrocytoma (NOS)
Fibrillary Astrocytoma
Pilocytic Astrocytoma
Ganglioglioma
Pleomorphic Xanthoastrocytoma

9 (3–17)
23 (4–64)
Number of patients
4
4
11
Number
Percentage
9
10

47.4
52.6

14
2
3

73.7
10.5
15.8

1
1
10
5
2

5.3
5.3
52.6
26.3
10.5

Table 2: Number of grade 2 & 3 toxicities probably, possibly or definitely attributable to vemurafenib
Adverse Event
Alanine aminotransferase increased
Alkaline phosphatase increased
Alopecia
Anorexia
Arthralgia
Aspartate aminotransferase increased
Blood bilirubin increased
Bullous dermatitis
Creatinine increased
Diarrhea
Dry skin
Electrocardiogram QT corrected interval prolonged
Erythema multiforme
Erythroderma
Fatigue
Fever
Gastrointestinal disorders - Acid reflux
Headache
Hypertension
Hypophosphatemia
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Grade 2
0
1
1
2
3
2

Grade 3
1
1
0
0
0
0

3
1
2
2
3
0
1
1
2
1
1
1
2
1

1
0
0
0
0
1
0
0
0
2
0
0
0
0

Oncotarget

Investigations - Plantar hyperkeratosis with pain
Lymphocyte count decreased
Mucositis oral
Nausea
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - keratoacanthomas
Palmar-plantar erythrodysesthesia syndrome
Photosensitivity
Pneumonitis
Pruritus
Rash maculo-papular
Skin and subcutaneous tissue disorders – Dermatitis, heat rash, photoonycholysis
Skin infection
Somnolence
Weight loss

Pharmacokinetics

1
2
1
1
0
1
0
0
1
12
3
1
1
1

0
1
0
0
1
0
1
1
1
10
0
0
0
0

regression model using AUCs as a predictor of PR+CR
was not significant given the observed variability.

A total of 19 subjects underwent pharmacokinetic
sampling. One subject with poor compliance was
removed from the final analysis. The steady-state AUC0median was 604 mg*h/L (range 329–1052 mg*h/L).
∞
Pharmacokinetic analysis demonstrated a significant
accumulation factor (approximately six-fold) over time
with each vemurafenib dose. In an attempt to correlate
exposure with response, patients were divided into those
having stable disease (SD) versus those having PR or CR.
Patients with SD had 11% lower AUCss (586 mg*hr/L)
compared to PR+CR (657 mg*hr/L). However, a logistic

Patient outcomes
Patient outcomes are reported for the 19 patients
treated. The median number of vemurafenib courses was
23 (range 3 to 63). Centrally reviewed best radiographic
responses included 1 CR, 5 PR, and 13 patients with
SD (Figure 1). Solid tumor component was measured
for determination of outcomes in 10 patients, with
the remaining 9 patients with no measurable solid
component undergoing measurement of solid/cystic

Figure 1: Depicted is the centrally reviewed “best response” per patient, based on the maximum change compared
to on study MRI. Each bar represents a patient. Grey bars depict patients treated on dose level 0 and red bars show subjects treated on
dose level-1.
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lesion for outcome determination. Figure 1 demonstrates
best response percent decrease in tumor size during
the course of treatment with vemurafenib. As shown
in Table 3, responses were durable with some patients
having continuous response for over 40 months. Cystic
lesions appeared to decrease more in size compared to
the solid lesions with vemurafenib therapy (Table 4).
Interestingly, we found that 10 of the patients in our
cohort who presented with contrast-enhancing tumors
were found to develop loss of enhancement during
treatment. Examples of radiographic responses are shown
in Figure 2, with representative solid, cystic, and mixed
solid/cystic lesions.
Of the 19 patients, only one patient (patient 10)
progressed on therapy (Table 3). Three patients (patients
1,3, and 6) came off drug because they had completed
therapy (originally defined as 12 months). Eleven patients
came off drug due to adverse events or patient decision.
Four patients remain on therapy. Of the fourteen patients
total that came off drug without progressive disease, only
four progressed during the 12-month protocol-defined
follow up period (Table 3).

suppressive effect in skin stem cells and loss of TGF-beta
signaling has been associated with SCC development
in adults treated with BRAF inhibitors [4]. Of note, one
of the six adolescents treated with vemurafenib in the
melanoma study also developed an SCC [10].
Only one of the 19 patients who participated in this
phase 1 study developed progression while on therapy.
Four patients remain on therapy with a mean of > 23
cycles of therapy. Our study found a high proportion of
objective radiographic responses that were durable,
with 1 CR, 5 PRs, and 13 SDs as the centrally-reviewed
best responses on therapy. The recently reported phase
I/IIa experience with the BRAFV600E inhibitor dabrafenib
in children with recurrent pediatric low grade glioma
reported 1 CR, 13 PR, 11 SD and two progressive diseases
as best responses in a cohort of 32 patients [12, 13]. This
is of particular interest as both drugs have been shown to
have poor CNS penetration in animal models [14]. It is
important to point out that the dabrafenib study used the
RANO criteria [15] to measure objective response, while
our study used a modified RANO criteria which included
tumor cysts in measurements.
One of the pressing issues facing the pediatric
neuro-oncology community is the optimal duration of
therapy for targeted agents. Of our fourteen patients that
halted treatment for either toxicity, patient decision, or
completion of therapy, four patients progressed during
12 months of follow up (Table 3). This suggests that
while responses can be durable in some patients after
halting drug, the ideal duration of therapy remains to
be determined. Of note, three of our four patients that
developed progressive disease off drug progressed within
four months of stopping therapy and so careful early
monitoring of patients who stop vemurafenib therapy is
warranted.
The first reported trial of a BRAF inhibitor
(sorafenib) for pediatric gliomas did not report any
secondary skin cancer formation, but instead reported a
significant stimulation of glioma tumor growth, which
we did not observe in our cohort [16]. The underlying
etiology of the sorafenib growth activation was thought to
be the presence of the KIAA1549: BRAF fusion protein
in the majority of enrolled patients. In contrast, our
study restricted eligibility to patients with the BRAFV600E
mutation and specifically excluded patients with the
KIAA1549: BRAF fusion, NF1, or any other known
RAS-opathy. Appropriate subject selection and detailed
preclinical characterization will be critical as targeted
therapies such as vemurafenib will be integrated in the
care of these children.
Pharmacokinetic analyses revealed similar drug
exposure and kinetics as in adult patients [17]. It is well
recognized there are often differences in pharmacodynamic
endpoints between pediatrics and adults. Limitations exist
when adult PK data and study endpoints are applied to a
pediatric population particularly in early phase trials where

DISCUSSION
The discovery of BRAFV600E mutations in a wide
spectrum of gliomas has led to optimism that these tumors
can be therapeutically targeted by potent inhibitors of
the mutant form of BRAF developed for the treatment of
melanoma. Herein, we report that vemurafenib is safe in
children with BRAFV600E gliomas and has promising antitumor efficacy.
Vemurafenib was approved for the treatment of
BRAF-mutant melanoma in 2011. Toxicities in adults
with melanoma include rash, arthralgias and secondary
malignancies (mostly SCC) [3]. The latter are of particular
concern when considering this therapeutic approach for
children, particularly for low grade tumors. In this phase
1 study, we found that the adult dose equivalent of 550
mg/m2 was well tolerated in children with a similar
safety profile seen in adult subjects. These results are
similar to the small study of vemurafenib in adolescents
with melanoma [10] and the recently reported pediatric
experience with Langerhans Cell Histiocytosis [11]. While
we encountered rash as a DLT in our initial cohort of
patients, this was not seen once we amended our protocol
with more universally used criteria for grading transient
grade 3 non-hematologic toxicities in patients receiving
BRAF inhibitors. Interestingly, one patient developed SCC
while on vemurafenib therapy in our study. This patient did
not have any concerning lesions at baseline and developed
facial SCC during cycle 4 of therapy. Biopsy confirmed
the diagnosis and genomic analysis of the SCC revealed
TGF-beta receptor homozygous deletions, without any
additional mutations affecting the RASA/RAF/MAPK
pathway. TGF-beta signaling is known to have a tumor
www.oncotarget.com
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Table 3: Patient Outcomes
Patient IDPathology1

Enrolled
On
Dose
treatment
(mg/m2)
date

Off
treatment
date2

Dose
Limiting
Toxicity

Best
Number
Response3 of cycles4

Reason Off
Date of
Treatment5 progression

1 - low grade
astrocytoma NOS

550

4/30/2014

5/27/2015

yes

PR

14

Completed
Therapy

9/1/2015

3 - pilocytic
astrocytoma

550

9/29/2014

9/2/2015

no

SD

12

Completed
Therapy

n/a

4 - pilocytic
astrocytoma

550

10/16/2014

+

yes

SD

64

n/a

n/a

5 - PXA

420

12/4/2014

8/13/2015

yes

SD

9

Adverse event

n/a

6 - fibrillary
astrocytoma

420

1/29/2015

12/28/2015

no

SD

12

Completed
Therapy

n/a

7 - pilocytic
astrocytoma

420

3/9/2015

5/31/2016

yes

SD

16

Patient
decision*

n/a

10 ganglioglioma

420

8/20/2015

9/15/2016

no

SD

14

Disease
progression

9/13/2016

11 - pilocytic
astrocytoma

420

9/30/2015

2/13/2019

no

SD

44

Patient
decision*

n/a

12 - ganglioglioma

420

12/8/2015

2/11/2019

no

SD

41

Patient
decision*

4/19/2019

13 - pilocytic
astrocytoma

420

12/31/2015

4/8/2016

no

PR

4

Adverse event

n/a

14- pilocytic
astrocytoma

420

4/14/2016

5/17/2018

no

SD

27

Patient
decision*

n/a

15 -ganglioglioma

420

5/12/2016

+

no

SD

43

n/a

n/a

16 ganglioglioma

420

6/15/2016

+

no

SD

42

n/a

n/a

17 -pilocytic
astrocytoma

550

9/29/2016

+

no

PR

38

n/a

n/a

18 - PXA

550

10/3/2016

8/8/2018

no

CR

24

Patient
decision*

n/a

19 - pilocytic
astrocytoma

550

11/10/2016

8/31/2018

no

SD

24

Patient
decision*

n/a

20 - pilocytic
astrocytoma

550

1/11/2017

10/26/2018

no

PR

23

Adverse event 12/11/2018

21 - pilocytic
astrocytoma

550

2/22/2017

4/25/2018

no

PR

15

Adverse event 12/10/2018

22- ganglioglioma

550

2/21/2017

11/8/2018

no

SD

22

Poor
compliance

n/a

1. NOS = not otherwise specified; PXA = Pleomorphic Xanthoastrocytoma
2. + Indicates that the patient remains on treatment as of 8/31/2019
3. Best response by imaging. PR = partial response; SD = stable disease
4. Median number of cycles = 23
5. Completion of protocol is defined as completing 12 cycles therapy.
*
Patient decision to stop treatment with stable disease after 12 or more cycles; treatment was allowed to continue
indefinitely as long as no toxicity, progression, or patient preference
www.oncotarget.com
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likelihood of success is low. Additionally, the historically
applied maximum tolerated dose (based on toxicity) is
often not equivalent to the maximum efficacious dose
(based on biomarkers). Given the lack of data for reliable
biomarkers in this rare disease population we specifically
designed the study collection of new data (both PK and
biomarkers) so that it can be combined with future trials
to enhance sample size and better defining exposureresponse relationships to optimize the use of this drug in

the pediatric population. While there was a correlation
between drug exposure and radiographic response, this
was not statistically significant in this cohort. Within the
phase 2 study that is actively ongoing we will also assess
if crushing vemurafenib for liquid formulation leads to
similar exposure which is an important assessment when
developing therapeutic options for children.
In summary, we report that vemurafenib is tolerable
and efficacious in children with recurrent low grade gliomas

Figure 2: Depicted are representative images of subjects treated on PNOC-002 demonstrating. (A) regression of a contrast
enhancing cystic lesion on a contrast, T1 weighted MR image over time; (B) regression of a solid/cystic lesion on a T2 weighted MR image
over time; (C) regression of a contrast enhancing solid lesion on a contrast, T1 weighted MR image over time.
www.oncotarget.com
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Table 4: Patients listed by their study numbers and shown are product of bi-dimensional tumor measurements for
each tumor lesion. Some patients had more than one lesion
Patient #

Cystic

1
3

−78

Solid/Cystic

Solid

Central review Best Response

−93

−79

PR

−37

SD

4

−11

5
6

−12

7

−73

10

−89

SD

−24

SD

7

SD
−29

−39

SD
SD

11

−45

SD

−16

SD

12

−32

13

−77

PR

14

−3

SD

15
16

−92

−100

17

−100

−80

−46

SD

−31

SD
PR

18

−100

CR

19

−34

SD

−54

PR

20
21

−82
−72

22

−64

PR

−39

SD

immunohistochemistry. Either fresh biopsy or archival
tissue were allowable for genotyping. Subjects must have
had disease that failed at least one prior therapy (including
radiation or systemic therapy) besides surgery and had to
have evidence of measurable disease on MRI. There was
no restriction for number of prior therapies. Subjects must
have recovered from acute side effects of prior therapies and
shown evidence of adequate bone marrow function (absolute
neutrophil count > 1000 cells/ul, hemoglobin > 8 gm/dl and
platelets > 75,000/ul), renal function within normal limits for
age and liver function (total bilirubin < 1.5 × ULN for age,
ALT and AST < 2.5 × ULN for age). Corticosteroids had to
be on a stable or decreasing dose prior to treatment. The QTc
on pre-treatment EKG had to be < 450 msec. Patients must
have been able to swallow tablets.
Children with active lesions suspicious for
keratoacanthoma or cutaneous squamous cell carcinoma
were excluded as were subjects with a known diagnosis
of Neurofibromatosis Type 1 or any other RAS-opathy
due to risk of paradoxical activation of tumor growth [18].
Further, prior exposure to a BRAF inhibitor constituted an
exclusion criteria.

with BRAFV600E mutations. The RP2D is 550 mg/m2
twice daily. An efficacy cohort in patients under 25 years
of age has recently completed accrual at the RP2D and
will be reported separately once data matures. The upper
age limit of the efficacy trial was extended to 25 years
to accelerate our accrual due to the overall rarity of the
disease being studied.

MATERIALS AND METHODS
Eligibility
The study was reviewed and approved by the
Institutional Review Board of each participating institution.
Verbal and written informed consent was obtained from
all participants or their parents with assent obtained for
the appropriately aged patients. Patients under 18 years
of age who had a histologically confirmed diagnosis of
a BRAFV600E-mutant primary brain tumor and Lansky
or Karnofsky performance score ≥ 60 were eligible.
Confirmation of the BRAFV600E mutation was required
in a CLIA-approved laboratory, either by sequencing or
www.oncotarget.com
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Treatment regimen, administration, and dose
escalation design

criteria [15]. Given that tumor cysts are commonly found
in low grade gliomas in children, these were not excluded
from measurements, as noted below. Measurable disease
was defined as lesions that can be accurately measured
in two dimensions with a minimum size of no less than
double the slice thickness. T2 FLAIR sequences were
used for disease assessment. All tumor measurements were
recorded in millimeters or decimal fractions of centimeters
and expressed as sum of products of largest diameter and
perpendicular diameter. Tumor measurements over time
were performed side by side in single session to maintain
corresponding plane of view. Many of the lesions had
both solid and cystic components. Tumor measurements
included measurement of a solid portion of the tumor
in lesions where the solid portion could be measured in
isolation. In tumors with multiple cystic components
that were inseparable from solid component, combined
measurement of the “solid/cystic” lesion was performed.
In tumors with only measurable cystic component,
measurement of the cyst was performed. Previously
irradiated lesions were considered non-measurable except
in cases of documented progression of the lesion since the
completion of radiation therapy. Complete response (CR)
was defined as complete disappearance of the target lesion
and no new lesions; partial response (PR) was defined as >
50% tumor reduction in product of bi-dimensional tumor
measurements of solid lesions. Progressive disease (PD)
was defined as an increase in product of bi-dimensional
tumor measurements > 25% in a solid lesion or the
appearance of a new lesion. For confirmation of CR and
PR, results needed to be sustained for 8 weeks.

Vemurafenib (RO5185426; PLX4032) was supplied
in 120 mg and 240 mg tablets by Genentech, Roche. Study
drug was administered orally twice daily (BID) in 28day cycles. Doses were adjusted based on body surface
area (m2) prior to each cycle. The starting dose level
(dose level 0) was 550 mg/m2 BID twice daily which was
equivalent to the adult recommended phase 2 dose (RP2D)
of 960 mg based upon an average adult BSA of 1.73 m2.
The maximum dose administered in this trial was capped
at 960 mg BID. Planned de-escalation dose levels included
dose level -1 420 mg/m2, dose level -2 330 mg/m2, dose
level -3 240 mg/m2 BID on a 28-day cycle and dose level
-4 240 mg/m2 day 1–7 and 15–21. Dosing nomograms were
used to accommodate the available pill sizes. Dose levels
-1 and -2 were only considered for study subjects if the
body surface area (BSA) was greater than 0.75 m2 and dose
level -3 and -4 only when BSA was greater than 0.9 m2.

Definition of dose limiting toxicity (DLT)
Toxicities were graded based on the NCI Common
Terminology Criteria for Adverse Events (CTCAE) version
4.0. Dose limiting toxicities (DLT) were based on adverse
events occurring in the first 28 day cycle. Hematologic
DLT was defined as any treatment related grade 4
hematologic toxicity with the exception of lymphopenia
and anemia, grade 3 neutropenia with fever; or grade 3
thrombocytopenia. Non-hematologic DLTs were initially
defined as any grade 3 or 4 related non-hematologic toxicity.
The protocol was subsequently amended to exclude grade
3 rash, diarrhea, infection, fever, or photosensitivity that
resolved to grade ≤ 2 within 7 days of appropriate medical
management in the DLT definition. This was based on
additional Genentech/Roche trial experience supporting that
these specific side effects can be well managed and should
not constitute a DLT. Any related grade 2 non-hematological
toxicity that persisted for more than 7 days and was
considered sufficiently medically significant or sufficiently
intolerable by patients to warrant treatment interruption and/
or dose reduction was also considered dose-limiting.

Pharmacokinetics
Pharmacokinetic sampling
Serial blood samples for PK were collected on days
1, 15 and 22 in cycle one of vemurafenib treatment. Whole
blood samples were collected at 2, 4, 8, and 24 hours postdose on day 1 with additional trough levels obtained
just prior to (t = 0) and 1-hour post dose on days 15. PK
collection was then repeated on day 22 with samples
collected just prior to (t = 0) and 2, 4, 8, and 24 hours
post-dose. Two milliliters of blood was collected at each
sampling time through a venous catheter and placed in a
heparinized tube for vemurafenib analysis. All samples,
within 30 minutes of collection, were centrifuged at
3400 rpm for 10 minutes at 4° C, and the plasma removed
and stored at –80° C until analysis.

Definition of response
Disease evaluation was by MR imaging on 1.5T or
3T clinical scanner that occurred at baseline followed by
every 2-months assessments. Standard clinical sequences
included 3 plane localizer, axial T2 weighted imaging,
3D fluid attenuated inversion recovery (FLAIR), and
T1 weighted imaging without and with intravenous
gadolinium. Subjects had the option to switch to every
3 months assessment after cycle 24. All images were
anonymized prior to a retrospective central review by
a study assigned neuroradiologist. Response criteria
used were a modified version of the published “RANO”
www.oncotarget.com

Bioanalysis
Plasma samples were analyzed by Covance Inc.
(Princeton, New Jersey) using a validated reverse phase
high performance liquid chromatography with mass
spectrometry. The assay was linear in the range of 25.0
to 50,000 ng/ml RO5185426 (vemurafenib, PLX4032).
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Samples with concentrations above the upper limit of
linearity were diluted and re-assayed. Samples with
vemurafenib levels reported below the lower limit of
quantification (LLOQ) were entered into the PK analysis
as half the value of the LLOQ. Assay accuracy, intraday, and inter-day variability ranged from 90.4–105.9%,
1.0–7.3%, and 1.8–6.1%, respectively.
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Pharmacokinetic analysis
A nonlinear mixed effects modeling approach was
used to describe vemurafenib time-plasma concentration
data. A recent publication from the same authors described
the population pharmacokinetic analysis in detail [19]. The
non-linear mixed effect modeling approach has been used
for characterizing the population pharmacokinetics in the
past half-century [20]. Briefly, a one-compartment model
with first-order absorption and elimination was applied,
with a bodyweight-based allometric component added
to all clearance and volume parameters using a fixed
exponent of 0.75 and 1, respectively. Between-occasion
variability was included in the final covariate model using
an exponential equation. The area-under-the-curve (AUC)
for each patient was derived from the empirical Bayes
estimate of individual clearance (CL) (AUC = Dose/CL).
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